| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4777 | 2014 |
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ... Journal of clinical oncology 30 (15), 1796-1804, 2012 | 2980 | 2012 |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2518 | 2019 |
| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 2430 | 2020 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1912 | 2018 |
| Association analysis identifies 65 new breast cancer risk loci K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ... Nature 551 (7678), 92-94, 2017 | 1505 | 2017 |
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk K Michailidou, P Hall, A Gonzalez-Neira, M Ghoussaini, J Dennis, ... Nature genetics 45 (4), 353-361, 2013 | 1313 | 2013 |
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ... The lancet oncology 15 (7), 747-756, 2014 | 1161 | 2014 |
| Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies CL Pearce, C Templeman, MA Rossing, A Lee, AM Near, PM Webb, ... The lancet oncology 13 (4), 385-394, 2012 | 1145 | 2012 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1084 | 2018 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 1063 | 2019 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 892 | 2022 |
| Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies XR Yang, J Chang-Claude, EL Goode, FJ Couch, H Nevanlinna, RL Milne, ... Journal of the National Cancer Institute 103 (3), 250-263, 2011 | 875 | 2011 |
| Breast cancer risk genes—association analysis in more than 113,000 women Breast Cancer Association Consortium New England Journal of Medicine 384 (5), 428-439, 2021 | 796 | 2021 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 787 | 2020 |
| Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer FJ Couch, SN Hart, P Sharma, AE Toland, X Wang, P Miron, JE Olson, ... Journal of clinical oncology 33 (4), 304-311, 2015 | 769 | 2015 |
| Prediction of breast cancer risk based on profiling with common genetic variants N Mavaddat, PDP Pharoah, K Michailidou, J Tyrer, MN Brook, MK Bolla, ... Journal of the National Cancer Institute 107 (5), djv036, 2015 | 709 | 2015 |
| Circulating tumor cells predict survival in early average-to-high risk breast cancer patients B Rack, C Schindlbeck, J Jückstock, U Andergassen, P Hepp, T Zwingers, ... Journal of the National Cancer Institute 106 (5), dju066, 2014 | 709 | 2014 |
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer K Michailidou, J Beesley, S Lindstrom, S Canisius, J Dennis, MJ Lush, ... Nature genetics 47 (4), 373-380, 2015 | 700 | 2015 |
| Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study M Untch, M Rezai, S Loibl, PA Fasching, J Huober, H Tesch, I Bauerfeind, ... Journal of Clinical Oncology 28 (12), 2024-2031, 2010 | 698 | 2010 |
